Individuals with significant body weight to lose, typically those with a BMI that qualifies for GLP-1 therapy and who have 30% or more body weight to lose, may benefit from the more aggressive metabolic intervention this combination provides
In this context, the present work evaluated the applicability of the commercially available upper MucilAir-HF and lower EpiAlveolar human lung models to be used as in vitro systems within a NAM toolbox to identify the bioactivity (i.e., in vitro PoD derivation) and risk of materials that may reach the respiratory tract and induce lung toxicity
When GLP-1 patients were compared with those not taking any of these medications, the GLP-1 group's recurrence risk was 14.5%, compared with 51.6% in the comparison group
Do patients regain weight after stopping GLP-1 medications
As a renowned trainer and speaker in the aesthetic field, she brings cutting-edge techniques to our patients, combining advanced technology with personalized care to achieve outstanding non-surgical results